The BCL6 proto-oncogene encodes a transcriptional repressor, which is required for germinal centers (GCs) formation and lymphomagenesis. Previous studies have been reported that the constitutive expression of BCL6 leads to diffuse large B cell lymphoma (DLBCL) through activation-induced cytidine deaminase (AID) mediated chromosomal translocations and mutations. However, other DLBCLs (45%) without structural variants were characterized by abnormally high level of BCL6 expression through an unknown mechanism. Herein, we report that deficiency in AID or methyltransferase 1 (DNMT1) triggers high level of BCL6 expression. AID-DNMT1 complex binds to À0.4 kb À0 kb region of BCL6 promoter and contributes to generate BCL6 methylation which results in inhibition of BCL6 expression. The proteasome pathway inhibitor MG132 induces accumulation of AID and DNMT1, causes decreased BCL6 expression, and leads to cell apoptosis and tumor growth inhibition in DLBCL cell xenograft mice. These findings propose mechanistic insight into an alternative cofactor role of AID in assisting DNMT1 to maintain BCL6 methylation, thus suppress BCL6 transcription in DLBCL. This novel mechanism will provide a new drug selection in the therapeutic approach to DLBCL in the future. Neoplasia (2020) 22 142-153 To measure the proliferation and apoptosis ability of DLBCL cells, cells were prepared and stained according to standard procedures. Vol. 22, No. 3, 2020 AID assists DNMT1 to attenuate BCL6 expression through DNA methylation J. Jiao et al. 143
Introduction
The affinity maturation in humoral response is critical for effective host defense against microbial infections and tumors. The process depends on two B lymphocyte differentiation mechanisms: Ig somatic hypermutation (SHM) and class switch DNA recombination (CSR) [1] [2] [3] [4] . Antigens stimulate naive B cells to develop to be germinal center B cells (GCBs), which leads to upregulation of activation-induced cytidine deaminase (AID) expression [5, 6] . The functions of AID could be summarized as following. Firstly, the deamination of AID converts cytosine in WGCW and WRC (W = A/T, R = A/G) motifs to uracil and produces U:G mismatch, then the error-prone repair cascade replaces the uracil in U:G mismatch to cause point mutations and double strand breaks (DSBs) for SHM and CSR, respectively [7] [8] [9] . Secondly, the deaminated 5mC by AID is recognized as a T and the generated T:G mismatch is finally corrected by C:G in error-prone repair pathway, which would implicate that AID involved DNA demethylation beyond DNA editing [10] [11] [12] [13] [14] . Third, AID prone to interact with some gene transcription regulatory factors (such as RAN PolII, Spt5), suggesting a alternative cofactor role of AID in regulating gene expression [15] [16] [17] . Thus, studies on AID are of considerable interest not only because of its central role in the generation of effective humoral immunity, but also because of its function in DNA methylation diversity or as a cofactor in GCBs, which potentiates AID mediated gene expression by epigenetic modifications or alternative cofactor role in B cell lymphoma.
AID's function is not restricted to Ig loci, about 25% of highly expressed non-Ig genes in GCBs are mutated by AID because AID targeted hotspot motif lacks strict specificity [18, 19] . Among these non-Ig genes, the proto-oncogene BCL6 is preferred to be deaminated by AID. BCL6 is a master regulator of the GC response to transcriptionally repress DNA damage response, cell cycle arrest and B cell maturation [20, 21] . In the development of GCBs, BCL6 positively regulates AID expression to mediate SHM in centroblasts formed dark zone or CSR in centrocytes formed light zone [20, 21] . The accumulation of DNA lesions originated from high level of AID indirectly involves in BCL6 degradation, which is a feedback to decrease AID expression [22] [23] [24] . As a consequence, B cells with the highest affinity antibodies for antigens exit light zone of GC and mature to be plasma cells or memory B cells [25] . Genomic aberrations of BCL6 or alterations of genes that modulate BCL6 expression during the GC reaction lead to sustained BCL6 activation, which promotes the development of GCderived lymphomas [26] . BCL6 overexpression is achieved through AID induced translocations in the first intron ($40%) or mutations of its promoter ($15%) in DLBCL patients [27] . However, in other DLBCLs ($45%) without BCL6 mutations or translocations [27] , whether AID involved in modulating BCL6 expression is yet to be confirmed.
Here, we used the AID-deficient DLBCL cells to identify that AID and DNMT1 formed a complex to maintain the methylation of BCL6 promoter, thus negatively regulated BCL6 transcription by binding to its À0.4 kb À0 kb promoter region. Moreover, the proteasome inhibitor MG132 blocked degradation of AID and DNMT1, and resulted in accumulation of AID and DNMT1, manifesting apparent cell apoptosis and tumor growth inhibition. Our results provide a mechanistic insight into the inhibition function of AID to subcutaneous DLBCL cell xenograft tumor, and identify undeveloped effect of MG132 in the repression of BCL6 expression and DLBCL treatment through inhibiting AID and DNMT1 degradation.
Materials and methods

Constructs and cells
The pCas9-AID and pCas9-DNMT1 recombinant transgenes with gRNAs for AID and DNMT1 were constructed by ligating gRNA for AICDA or DNMT1 to pL-CRISPR.EFS.PAC plasmids, respectively. The sequences of gRNAs for AICDA or DNMT1 were listed in the Supplementary Table S1. The gRNA sequences were commercially confirmed (Sunny). pWPI-AID-GFP and pWPI-BCL6-GFP lentivirus constructs were ligated AID and BCL6 cDNA to pWPI-GFP plasmids, respectively. The sequences of primers for amplifying AID and BCL6 cDNA as following: AID_F (5 0 -CTGGACACCACTATGGACAGCCTCTTGATG-3 0 ),
The SU-DHL-4, OCI-LY10, OCI-LY19 and OCI-LY7 DLBCL cell lines were purchased from BeNa Culture Collection (BeNa, #BNCC340176, #BNCC337742, #BNCC338225, #BNCC340174). Cells were cultured at 37°C with 5% CO 2 in IMDM (Hyclone) supplemented with 10% fetal bovine serum (FBS) (Sigma), non-essential amino acids, and penicillin-streptomycin (1%), and b-mercaptoethanol (50 lM). 293 T cells were stored in our laboratory and cultured in DMEM (Hyclone) supplemented with 10% FBS, non-essential amino acids, and penicillin-streptomycin at 37 ℃ with 5% CO 2 . In nutrition deficiency treatment, cells were treated by culturing in FBS free IMDM (Hyclone) supplemented with 1% penicillin-streptomycin. To generate stable DLBCL cell lines with integrated pCas9-AID and pCas9-DNMT1 transgenes, the plasmids pCas9-AID and pCas9-DNMT1 were transfected into 293 T cells being seeded 24 hours before transfection at a density of 1 Â 10 6 cells per 5-cm plate, cotransfected with the DR9 and pVSVG helper plasmids using the X-tremeGENE HP DNA transfection reagent (Roche, #06366236001). Supernatants were collected 72 hours after transfection. 1 Â 10 6 DLBCL cells were infected with a freshly prepared AID or DNMT1 knock out lentivirus by performing a 1000 g spin at room temperature for 90 minutes in the presence of 10 lg/ml polybrene. Stably integrated DLBCL cells were selected by puromycin (0.4 lg/ml) for 5 days. To generate AID or BCL6 over-expressing DLBCL cell lines, 1 Â 10 6 DLBCL cells were infected with AID or BCL6 expressing lentivirus for 5 days and then were sorted by BD AriaIII.
Cells were treated with 5-Azacytidine (10 lM) (Selleckchem, #S1782) for 24 h. Combined treatment with MG-132 (10 lM) (Selleckchem, #S2619) was done for another 8 h following pre-treatment with 5-Azacytidine (10 lM) for 16 h. Control cells were only treated with a solvent (DMSO).
RNA extraction and quantitative RT-PCR
Total RNA of DLBCL cell pellets was extracted with TRIzol (Invitrogen, #15596026) according to the manufacturer's instructions. cDNA was then synthesized with PrimeScript™ RT reagent Kit (TaKaRa, #RR037A), according to the manufacturer's protocol. Quantitative PCR was performed with real-time PCR using Mx3000P (Agilent Technologies). Primers were listed in Supplementary Table S2 . The relative mRNA level of genes were calculated according to the formula 2 À44Ct using bactin as an internal control.
Genomic DNA isolation and bisulfite sequencing
Genomic DNA was extracted from 1 to 5 Â 10 6 cells using the Genomic DNA Extraction Kit (TaKaRa, #D824A) according to the manufacturer's protocol. The genomic DNA was converted by bisulfite treatment using the EZ DNA Methylation-Gold Kit (Zymo Research, #D5006) and amplified by PCR with the EpiTaq™ HS Kit (TaKaRa, #R110A). The CpG island containing CpG sites in BCL6 promoter were predicted according to the website for methylation primer designing (http://www. urogene.org/methprimer/). The primer sequences used for analyzing the methylation status of 4CpG sites and 17 CpG sites in BCL6 promoter regions were BCL6-4 meth_F (GTTTTGGTTATGAGAGTTTTT-TAAG) and BCL6-4 meth_R (AAAATACATTACCAACAACATT TTC); BCL6-17 meth_F (GTTATTTAGAAGGATAGGGGAAGG) and BCL6-17 meth_R (TCTAAAAACTATCTAACCCCAAACC). Amplicons were visualized on a 1.0% agarose gel. They were then excised, purified with the OMEGA Gel Extraction Kit (OMEGA, #D2500-01), and cloned into the pMD Ò 18-T vector (TaKaRa, #D103A). DNA containing amplicon inserts were identified by digestion with Xbal and SalI restriction enzymes and sequenced commercially (Sunny). Sequence analysis showed a bisulfite-modification efficiency of 99-100%.
The À0.92 kb to 0 kb of BCL6 gene was amplified from genomic DNA and cloned into the pMD Ò 18-T vector (TaKaRa, #D103A). After confirmation by Xbal and SalI restriction enzymes, the vector with the target fragments were commercially sequenced (Sunny). The primers were BCL6 TSS_F (TTGTCCCAAGTCACACTGGA) and BCL6 TSS _R (AGTGCAAATCATAGCTGGGG).
The fragments containing the first intron of BCL6 gene were amplified from genomic DNA by long-range PCR according to the manufacturer's protocol of TaKaRa LA PCR™ Kit Ver.2.1 (TaKaRa, #RR013A). The sequences of primers were BCL6 intron 1_F (ATTCTCCATGTCTGCC CCAA) and BCL6 intron 1_R (ACTCGCCTCTCTAACCCTAC).
Measuring the ability of cells to proliferate involved the use of anti-CFSE (carboxyfluorescein succinimidyl ester) (BD eBioscience, #C34554) to stain the cells in advance for 6 hours. The cells were then washed twice with 1 Â PBS at 4°C and analyzed by flow cytometry. Nutrition deficiency was performed to measure apoptosis. Cells were collected and washed twice with 1 Â PBS at 4°C, incubated with anti-Annexin V and anti-7-ADD (BD eBioscience, #559763) for 15 minutes at room temperature. Finally, the cells were resuspended in flow cytometry buffer and analyzed by flow cytometry. All data were collected using a CytoFLEX Flow Cytometer (Beckman Coulter).
Immunoblot analysis
Cell pellet was lysed in RIPA buffer [50 mm Tris-HCl (pH 8.0), 0.15 m NaCl, 1% Triton X-100, 0.5% NaDoc, 0.1% SDS, 1 mm EDTA, 1 mm EGTA, 1 mm PMSF (Amersco) and 1 lg/ml Pepstatin A (Sigma) protease inhibitors]. The cells were then sonicated using BioruptorTMUCD-200 (Diagenode) for 15 min at a low speed. Cell lysates were centrifuged for 20 min at 15 000g at 4°C, and the protein supernatant was collected. Protein samples were loaded on a 10% (w/v) Tris-HCl SDS-PAGE gels for electrophoresis, transferred to PVDF membrane (Millipore), blotted, and then probed with anti-AID (CST, #4959), anti-BCL6 (Abcam, #ab33901), anti-DNMT1 (Abcam, #ab13537), anti-DNMT3A (Abcam, #ab2850), anti-DNMT3B (Abcam, #b2850), anti-Caspase 3 (Abcam, #ab13586) antibodies. Anti-GAPDH (Abcam, #ab9485) was used as a loading control. The signal was further detected using the secondary antibody of goat anti-Rabbit, goat anti-Rat, goat anti-Mouse IgG conjugated with horseradish peroxidase (Thermo Fisher). Band signal was visualized by Immobilon™ Western Chemiluminescent HRP substrate (Millipore). Integrating optical density was analyzed using gel-pro analyzer software (Media Cybernetics) and ratios of bands were all referenced to the loading control.
Immunoprecipitation
Briefly, Total protein was extracted as described in the part of immunoblot analysis. After pre-clearing the chromatin with Dynabeads Protein G beads (2 Â) (Invitrogen, #10003D), set a part of the aliquot aside as the input sample. Proteins from 5 Â 10 6 cells were then incubated with 5 lg specific antibody or normal goat IgG (Santa Cruz, #sc2346) for overnight at 4℃. Anti-AID (Abcam, #ab59361), anti-DNMT1 (Abcam, #ab13537), immune complexes were pulled down through incubation with Dynabeads Protein G beads (2 Â ) (Invitrogen, #10003D) for 3 hours. The beads were washed at 4°C for ten times with RIPA buffer containing different concentration of NaCl. The pulldown proteins were denatured at 100°C, and loaded on SDS-PAGE gels to perform immunoblot.
Chromatin immunoprecipitation
The chromatin immunoprecipitation (ChIP) was carried out according to the methods reported by Ji Y [28, 29] . Briefly, 30 Â 10 6 cells were crosslinked with 1% HCHO (Sigma) for 15 min at room temperature, and the reaction was terminated with 0.125 m glycine. The precipitate was washed, resuspended in RIPA buffer and sonicated to fragment DNA of 0.3-0.5 kb. After pre-clearing the chromatin with Dynabeads Protein G beads (2 Â) (Invitrogen, #10003D), about one tenth of the aliquot was stored up as the input sample. The remnants were incubated with 5 lg specific antibody or normal IgG overnight at 4°C. Immune complexes were pulled down with Dynabeads Protein G beads (2 Â) (Invitrogen, #10003D). After reversal of cross-links and purification of the DNA, qPCR was performed using SYBR Premix Ex Taq™ II (TaKaRa, #DRR081A) with Mx3000 thermocycler (Agilent Technologies). The primer sequences used for qPCR were ChIP-BCL6_F (CCTTCGCTGTAG-CAAAGCTC) and ChIP-BCL6_R (AACCTCTCGCTCCCTTTTGT). Input samples were diluted so that each IP and input sample would give approximately equal qPCR signals. Using standard curves generated for each region analyzed in each experiment, the amount of DNA obtained from immunoprecipitates and the input chromatin was calculated. ChIP-qPCR signals were expressed according to the following equation: (IP/Inputcorr)/positive control = (((IPspecific antibody À IPIgG)/ Input) Â 1000)/positive control. ChIP experiments were performed with antibodies for anti-AID (Abcam, #ab59361), anti-DNMT1 (Abcam, #ab13537) and normal goat IgG (Santa Cruz, #sc2346).
Construction of luciferase plasmids and transient reporter assay
The fragments of promoter (p) and the sub-regions 1-4 (p1, p2, p3 and p4) of BCL6 gene were amplified by PCR from genomic DNA. Primers used were listed in Supplementary Table S3 . The amplified fragments were digested with MluI and XhoI and were cloned into the pGL3-basic vector upstream of the firefly luciferase-encoding region. The constructed vector sequences were commercially confirmed (Sunny, China). SU-DHL-4, OCI-LY10 and OCI-LY19 cells were transiently transfected by equimolar amounts of reporter constructs with BCL6 promoter segments and the pGL3-basic vectors together with the X-tremeGENE HP DNA transfection reagent (Roche, #06366236001). Cells were cultured for 72 hours prior to collection. Luciferase activity was measured by the Luciferase Assay kit (Promega, #E1500) with an EnVision 2103 Multilabel Reader (PerkinElmer). Luciferase activity was presented as the`fold change' relative to that obtained with pGL3-basic.
In vivo tumor cell engraftment and treatment of mice NOD/SCID (Non-obese diabetic/severe combined immunodeficiency) mice were maintained in specific pathogen-free facilities at the Xi'an Jiaotong University Laboratory Animal Center. A murine model of human DLBCL was established by subcutaneous injection of 2 Â 10 7 DLBCL cells into the right flank of NOD/SCID mice. The tumor growth was monitored by measuring tumor size in two orthogonal dimensions. Tumor volume was calculated using the formula ø(long dimension)(short dimension) 2 . MG132 (10 lM) therapy was initiated when the average tumor volume reached 80 mm 3 -100 mm 3 . The DLBCL tumor-bearing NOD/SCID mice were divided into control group (n = 5) and treatment group (n = 5). The mice in treatment group were intraperitoneally injected with MG132 (50 mg/kg), while the mice in control group was received an intraperitoneal injection with an equal volume of solvent (4% DMSO + 30% PEG300 + 20% Propylene glycol + ddH 2 O). Tumor volume was continuously monitored twice every weekly (on Mondays and Wednesdays). All of the mice were euthanized 24 days post MG132 therapy. The tumors in the control and treatment groups were excised and weighed. All animal procedures were approved by the Institutional Animal Care and Use Committee of Xi'an Jiaotong University.
Statistical analysis
Unpaired t-test and ANOVA multiple tests were performed with GraphPad Prism 6.0 (GraphPad Software, LaJolla, CA, USA). Data were considered statistically significant if p values were less than 0.05, as indicated.
Results
AID loss impairs DLBCL cell apoptosis by elevating BCL6 level
To explore the action of AID in DLBCL cells without BCL6 translocations, genomic DNA derived from SU-DHL-4, OCI-LY10 and OCI-LY19 DLBCL cell lines were amplified for 12.7 kb`major breakpoint region' spanning BCL6 intron 1 by using long-range PCR, respectively [30] (Fig. S1A ). SU-DHL-4 cells were used as a negative control because previous studies have been reported that they were lack of rearrangement for BCL6 locus, while OCI-LY7 cells carrying BCL6 rearrangement were taken as positive control [31] . The relative density of the PCR products for BCL6 intron 1 showed insignificant difference in OCI-LY10 and OCI-LY19 compared to that in SU-DHL-4, indicating the selected DLBCL cells lacked BCL6 translocations ( Fig. S1B ). To further exclude the absence of rearrangement in both alleles of BCL6 gene, semiquantitative PCR for amplifying BCL6 intron 1 products was performed to SU-DHL-4, OCI-LY10 and OCI-LY19 cells (Fig. S1C ). We observed that the relative density of PCR fragments derived from OCI-LY10 and OCI-LY19 cells were equal to that from SU-DHL-4 cells (Fig. S1D ). These results demonstrate that the BCL6 translocations are absent in the three selected SU-DHL-4, OCI-LY10 and OCI-LY19 DLBCL cell lines.
The DLBCL cells were transduced using CRISPR/Cas9 with gRNAs for AID to generate AID knockout SU-DHL-4 (4AIDKO), OCI-LY10 (10AIDKO) and OCI-LY19 (19AIDKO) cell lines, respectively (Fig. S2A ). The levels of mRNA and protein for AID were significantly depleted in the three AIDKO DLBCL cells compared to their wild-type (WT) counterparts ( Fig. 1A to D). To determine whether AID loss had an impact on cellular function, apoptosis of AIDKO DLBCL cells were rigorously examined using Annexin V staining in absence of nutrition. The three AIDKO cells presented approximately 30% less of Annexin V + populations compared to that derived from WT ones (p < 0.001) ( Fig. 1E ), indicating reduced apoptosis of DLBCL cells after AID deficiency. The cells labeled with CFSE were monitored and dye dilution was tracked by flow cytometry, the collected data showed that the cell division rates of 4AIDKO, 10AIDKO and 19AIDKO cells were faster than those of WT cells (Fig. S2B ). In addition, the transcripts of proapoptosis genes (FAS, BIMEI, BMF, BAD and BAX) obviously dropped in AIDKO cells (all p < 0.05) ( Fig. S2C) . Meanwhile, the transcription levels of anti-apoptotic genes (BCL2, A1, BCLW, CLAP1, CFLIP, MCL1) apparently increased in AIDKO cells (all p < 0.05) ( Fig. S2D ). Taken together, these results suggest that AID deficiency impairs the DLBCL cell proliferation.
To investigate whether AID was involved in BCL6 expression in the DLBCL cells, the mRNA and protein levels of BCL6 were analyzed in WT and AIDKO DLBCL cells, respectively. We observed that the expression levels of BCL6 increased 5 to 15 folds in AIDKO cells in comparison to that in WT cells ( Fig. 2A) . The specific elevated BCL6 level in three AIDKO DLBCL cells was confirmed by immunoblots (Fig. 2B) . The data suggest that AID deficiency potentiates to up-regulate oncogenic BCL6 expression in DLBCL cells with higher proliferative rate.
The deamination of AID has no role for DNA demethylation on BCL6 gene
To evaluate whether AID deamination contributed to BCL6 expression by mutations, genomic DNA was purified from WT and AIDKO DLBCL cells, respectively. It has been reported that þ1-kilobase (kb) segment of the major transcription start site (TSS) for each gene is the preferred region for AID targeting [19] . A 0.92 kb BCL6 segment, located upstream of TSS, was selected to amplify, sequenced and analyzed for point mutations with 34 960 nucleotides of sequence (Fig. 2C) . The mutation frequency for BCL6 analyzed from WT cells displayed 1.9 Â 10 À2 mutations per base pair (bp). AIDKO cells yielded about 1.34 Â 10 À2 mutations per bp (Fig. 2D ). Comparing to the data, we conclude that BCL6 mutation frequency shows insignificant difference between WT cells and AIDKO cells AID involves in DNA demethylation process and usually targets promoters in B or non-B cells [5, 10] . To verify the epigenetic role of AID related to BCL6 expression in AIDKO cells, the bisulfite sequencing was used to examine methylation status of BCL6 promoter region (Fig. 2E) . The methylation level of the 4 CpG sites located in the À0.51 kb to À0.24 kb did not increase along with AID deficiency. Instead, it slightly decreased in AID-deficient DLBCL cells (Fig. 2F) . However, the methylated levels of 17 CpG sites located in the À1.07 kb to À0.84 kb did not show significant difference in SU-DHL-4 cells with or without AID expression ( Fig. S3A and B ), suggesting an indirect role of AID in methylation on CpG sites closed to TSS in BCL6 promoter. There is no tight link between AID deamination activity and BCL6 demethylation.
AID assists DNMT1 to attenuate BCL6 expression via maintaining DNA methylation
To search the factors assisted by AID involved in BCL6 methylation, we focused on conserved DNA methyltransferases, including DNMT1, DNMT3A and DNMT3B, which play the most important roles in de novo synthesis and maintenance of DNA methylation in mammal cells [32] [33] [34] . To gain more insights into the mechanism of DNA methylation controlling BCL6 expression in DLBCL cells, we demonstrated that DNMT1 but not DNMT3A or DNMT3B dramatically reduced in AIDKO DLBCL cells compared to WT counterparts ( Fig. 3A and B;  Fig. S4A ). To identify the involvement of endogenous DNMT1 in BCL6 methylation, we created DNMT1 knockout SU-DHL-4 (4DNMT1KO), OCI-LY10 (10DNMT1KO) and OCI-LY19 (19DNMT1KO) cell lines using CRISPR/Cas9 technique ( Fig. 3C and  D; Fig. S4B ). The BCL6 expression was up-regulated in contrast to decreased DNMT1 level in the three DNMT1KO DLBCL cells ( Fig. 3C and D; Fig. S4C ). To test whether AID synergized DNMT1 to inhibit BCL6 expression, 4WT and 4AIDKO DLBCL cells were treated with a DNMT1 inhibitor 5-Azacytidine [35] , we showed that BCL6 mRNA level was at the peak following the repression by both AID and DNMT1 (Fig. 3E) . The immunoblot analysis also confirmed a promoting effect to BCL6 expression when both AID and DNMT1 were absent in DLBCL cells (Fig. 3F, lane 4, 8 12) . These findings demonstrate that AID and DNMT1 collaborate to inhibit BCL6 expression in DLBCL cells.
Following the revelation of a reduced DNMT1 level in AIDKO cells (Fig. 3A) , we hypothesized that AID regulated DNMT1 expression at either a transcription or a post-transcription level. The transcripts of DNMT1 exhibited unconspicuous change in three DLBCL cells in presence or absence of AID (Fig. 3G) , arguing that AID modulated DNMT1 expression at a post-transcription level. We used the proteasome inhibitor, MG132, which is used to inhibit protein degradation. The AID and DNMT1 expression increased in the three DLBCL cells after MG132 treatment (Fig. 3H, lane 3, 7 and 11 ). Meanwhile, both AID and DNMT1 were disappeared following 5-Azacytidine treatment in DLBCL cells (Fig. 3H, lane 2, 6 and 10) . However, the 5-Azacytidine induced depletion was rescued by MG132 treatment (Fig. 3H, lane 4, 8 and  12 ). We interpreted these findings that AID and DNMT1 stabilized each other to avoid their degradation. To confirm the existence of AID-DNMT1 complex in DLBCL cells, we performed immunoprecipitation (IP) experiments to reveal the association of AID and DNMT1. Pre-clearing of nuclear extracts using anti-AID or anti-DNMT1 removed the complexes without AID or DNMT1. The complexes hosted by anti-AID showed the existence of DNMT1 (Fig. 3I) . The DNMT1-containing complexes hosted by anti-DNMT1 revealed AID existence (Fig. 3J) . The results suggest that AID and DNMT1 co-reside in DLBCL cells to form complexes. Taken together, the data demonstrate that AID assists DNMT1 as a cofactor to attenuate BCL6 by maintaining DNA methylation.
AID-DNMT1 complex binds to À0.4 kb to 0 kb BCL6 promoter region To investigate whether AID and DNMT1 bound to BCL6 promoter directly, Chromatin Immunoprecipitation (ChIP) assays were performed using antibodies against AID and DNMT1. Immunoprecipited DNA was analyzed by qPCR with primers that amplify two fragments which locate in À0.43 kb -À0.23 kb (site 1) and À0.21 kb -À0.03 kb (site 2) regions ( Figure S5A ). AID and DNMT1 binding to the two sites were extremely higher in SU-DHL-4, OCI-LY10 and OCI-LY19 cells than that in their KO counterparts, respectively (both p < 0.05) ( Fig. 4A and  B) . We additionally revealed that enrichment of H3K4me3, which marked active promoter, largely presented in both WT and AIDKO cells ( Figure S5B ), suggesting that AID-DNMT1 complex binds to H3k4me3 enriched BCL6 promoter directly.
To identify whether the distinct recruitment of AID contributed to the repression of BCL6 transcription, a 1.8 kb BCL6 promoter segment (p) (positions À1.8 kb to À0 kb) was amplified and ligated to constructs with a firefly luciferase-encoding region (Fig. 4C ). We observed that the construct with p induced more than 3 folds higher relative luciferase activity in AIDKO DLBCL cells than that in WT DLBCL cells (p < 0.05) ( Fig. 4D to F) , indicating AID loss induced BCL6 promoter-driven transcription initiation. To further test the potential AID targeted minimum sequence needed for repressing BCL6 transcription, we generated four luciferase reporter assay systems containing four small segments derived from the 1.8 kb region, including p1 (positions À0.4 kb to 0 kb), p2 (positions À0.9 kb to À0.4 kb), p3 (positions À1.4 kb to À0.9 kb) and p4 (positions À1.8 kb to À1.4 kb) (Fig. 4C ). The construct with p1 induced approximately 2.5 to 3 folds more relative luciferase activity in AIDKO DLBCL cells than that in WT DLBCL cells (all p < 0.05), while other three segments (p2, p3 and p4) had no function in arousing luciferase activity ( Fig. 4D to F ), suggesting p1 was the specific region that AID functionally repressed BCL6 expression. Similarly, we tested p and p1 regions mediated nearly 3 to 5 folds more relative luciferase activity in DNMT1KO cells than WT cells ( Fig. 4G to I) , indicating the minimal sequence of AID and DNMT1 targeting is À0.4 kb to 0 kb in BCL6 promoter. Together, these results suggest AID-DNMT1 complex abrogates BCL6 transcription level by binding to the À0.4 kb À0 kb region of BCL6 promoter in DLBCL cells.
MG132 suppresses DLBCL growth in vitro and in vivo
On the basis that AID-DNMT1 complex inhibited BCL6 transcription in DLBCL cells, we asked whether MG132 suppressed transcription level of BCL6 was capable of antilymphoma activity in DLBCL. After the treatment of WT, AIDKO2 and DNMT1KO3 cells derived from SU-DHL-4, OCI-LY10 and OCI-LY19 cell lines with MG132, the trend of cell apoptosis was observed by analyzing Annexin V staining. The apoptosis ratios of MG132 treated WT, AIDKO2 and DNMT1KO3 DLBCL cells apparently increased (Fig. 5A) . The cytotoxicity of MG132 to WT DLBCL cells were superior to either AIDKO2 or DNMT1KO3 cells, indicating that MG132 killing DLBCL cells through accumulating AID and DNMT1 (Fig. 5A ). The active caspase 3 level rose after MG132 treatment (Fig. S6A ). In addition, the anti-apoptotic gene expression including BCL6 as well as BCL2 also dropped (p < 0.05) (Fig. S6B) . Several apopto- sis associated genes (for example, BIMEI, BMF, BOK, BAD, PUMA, BAK) level apparently increased (all p < 0.05) (Fig. S6C) . In general, MG132 has the ability to induce DLBCL cell apoptosis by inhibiting DNMT1 and AID degradation through proteasome pathway.
To determine whether MG132 could affect lymphoma growth in vivo, the murine WT, AIDKO2 and DNMT1KO3 DLBCL cells xenogeneic tumor model were generated. When the tumor volume reached to 80 mm 3 -100 mm 3 , the intraperitoneal administration of solvent or MG132 to mice was performed (Fig. S6D ). The administration of MG132 strongly impaired the expansion of WT DLBCL cells, manifesting reduced tumor volume and tumor weight. In contrast, solvent treatment completely failed to exert any inhibitory effects on the progression of WT DLBCL cells, showing big tumor volume and much tumor weight ( Fig. 5B and C) . However, the tumor volume and tumor weight from AIDKO2 and DNMT1KO3 cells xenogeneic tumor models showed relatively inefficient inhibition effect after MG132 treatment, indicating that MG132 inhibited DLBCL xenogeneic tumor growth via increasing AID and DNMT1 activity at the BCL6 promoter region in vivo. These findings indicate that MG132 has a significant therapy function in the treatment of DLBCL disease in vitro and in vivo.
Discussion
Many experiments in a variety of systems have confirmed the role of AID in plastic diversity of DNA methylation and corresponding gene regulation in normal GCBs. DLBCLs originate from GCBs and are characterized by BCL6 dysregulation [5, 11, 36] . However, until now, the connections are limited between AID's epigenetic role or cofactor role and BCL6 expression in DLBCL. The present results here demonstrate that AID assists DNMT1 to bind to À0.4 kb À0 kb segment of BCL6 promoter and mediates BCL6 to undergo DNA methylation. The process consequently inhibits BCL6 expression in DLBCLs without BCL6 mutations or translocations, thereby providing a mechanism for the therapy of proteasome inhibitor MG132 to DLBCL by inducing accumulation of AID and DNMT1. The data here reveal that an alternative cofactor role of AID to DNMT1 in maintaining BCL6 methylation in DLBCL.
Deregulated BCL6 expression is commonly associated with DLBCLs, due to its promoter mutations, chromosomal translocations or epigenetic modifications or cofactor role in gene expression [22, 37, 38] . Therefore, understanding BCL6 deregulation from AID mediated gene expression regulation by epigenetic alteration or alternative cofactor role could help in revealing molecular pathogenesis of DLBCLs beyond AID associated mutations or translocations [27] . Studies on AID targeting in the genome have been demonstrated that AID occupies at a large number of promoters beyond Ig loci, implying AID might be involved in controlling gene expression [39] . Here, we show that AID and DNMT1 formed complex to bind to BCL6 promoter ( Fig. 3 and Fig. 4 ). This indicates that the occupancy of AID-DNMT1 complex on BCL6 promoter efficiently impedes the access of transcription initiation factors to BCL6 locus, thus suppresses BCL6 transcription in DLBCL. Notably, the data provided here indicate that the methylated CpG sites (À0.51 kb to À0.24 kb) are located in the AID-DNMT1 complex binding region in BCL6 promoter (À0.4 kb À0 kb) ( Fig. 2 and Fig. 4 ). On the basis of our findings and those of others [33] , we suggest that DNMT1 instead of AID is a key factor to maintain methylation of BCL6 promoter in DLBCL (Fig. 2, Fig. 5 and Fig. S3 ). AID recruits DNMT1 to the À0.4 kb À0 kb region of BCL6 and assists DNMT1 as a cofactor to maintain the methylation of BCL6 promoter, thus represses BCL6 expression in DLBCL.
The role of AID to BCL6 in DLBCL is depicted as AID mediated BCL6 mutations or translocations inducing uncontrolled BCL6 expression [27, [37] [38] [39] . We excluded structural variants of BCL6 locus in the DLBCL cells used in our experiments (Fig. 2) . Our results demonstrate that AID assisted DNMT1 to inhibit BCL6 transcription through maintaining DNA methylation on its promoter (Fig. 3, Fig. 4 and Fig. S3 ). It seems that one contradiction between the common deamination function of AID to BCL6 and our results appeared. One likely explanation for this is that the reported high expression of AID in DLBCL is the effect of its antagonism to BCL6 high expression. Our hypothesis was confirmed by constructing BCL6 and AID over-expressing DLBCL cell lines. The data indicate that overexpressed BCL6 increases AID levels ( Fig. S7A  and B ), while increased AID forces to reduce BCL6 expression ( Fig. S7C and Fig. 2) .
For the initiator of DLBCL pathogenesis, we propose that AID offtarget might be the main driver of DLBCL with BCL6 translocations, while BCL6 deregulation may be the main inducer of DLBCL without BCL6 translocations. It seems that AID has two edges in DLBCL. For DLBCL without translocations, up-regulation of AID might be a positive way to perform antagonism to BCL6 induced DLBCL deterioration. Therefore, we suggest a AID-BCL6 regulation loop in DLBCL. Firstly, BCL6 deregulation drives the deterioration of DLBCL, high expression of BCL6 mediate up-regulation of AID. Secondly, to antagonize BCL6 driven DLBCL, highly expressed AID consecutively down-regulates BCL6 level through forming complex with DNMT1 (Fig. S7D) .
In the last decade, many novel therapeutic regimens have been developed to treat DLBCL, such as radio-and/or immuno-, multi-agent chemotherapy, and even R-CHOP [40] [41] [42] [43] . Clinical therapeutic strategies for DLBCL by targeting BCL6 through BCL6 inhibition or degradation are well appreciated [44] [45] [46] [47] . However, these conventional therapeutic methods have less mitigation effect in cancer therapy, there are still more than 30% of patients, who are non-responsive to the available treatment or will develop relapsed/refractory disease with resistance [48] . Based on the data shown here, we attempted to find another effective therapeutic approach for DLBCL. Therefore, a proteasome inhibitor, MG132, was used here to treat DLBCL. Indeed, it is found from the treatment data in vitro and in vivo that AID and DNMT1 accumulation by MG132 treatment can slow down the disease progression or even treat DLBCL ( Fig. 5 ), suggesting a new selective therapy strategy in clinical DLBCL treatment. The MG132 treatment suppressed BCL6 transcription in DLBCL, which is superior to and eliminated the post-transcription degradation of BCL6 protein.
Here, our data support a possible model by which the interaction of AID and DNMT1 controls BCL6 transcription in DLBCL: (1) the loss of AID or DNMT1 leads AID-DNMT1 complex to disassociate from BCL6 promoter. As a consequence, the methylated BCL6 promoter undergoes demethylation and the expression of BCL6 increases in DLBCL (Fig. 6A). (2) AID-DNMT1 complex is recruited to the À0.4 kb À0 kb region of BCL6 promoter, AID assists DNMT1 to maintain methylation of BCL6 promoter and inhibits BCL6 expression in DLBCL (Fig. 6B). (3) MG132 mediates BCL6 repression by avoiding AID and DNMT1 degradation. AID-DNMT1 complex has more opportunity to be recruited to BCL6 promoter, and drives dynamic methylation (Fig. 6C ).
In conclusion, our work provides a novel mechanism of AID and DNMT1 cooperation maintains the methylation of BCL6 promoter, which in turn suppresses BCL6 expression in DLBCL. Our model might be useful for clinical staging of DLBCL by using AID and BCL6 proteins. In addition, blockade of AID and DNMT1 degradation by proteasome inhibitor MG132 could induce DLBCL cell apoptosis and would develop an effective therapeutic strategy for DLBCL in future.
